TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07557927: A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus

Sponsor: Kunming Pharmaceuticals, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,176,000

Rescue Site Savings

+$4,726,500

Unlock Full NCT07557927 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07557927 Rescue Dossier →